Vebeglogene autotemcel not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- A gene therapy: delivers a gene into the patient's cells so they make a protein they lack.-gene: gene therapy substances WHO name stem
- How it’s given
- “Autologous HSPCs transduced with self-inactivating lentiviral vector encoding functional HBB gene and resuspended in cryopreservative solution in the final immediate container for the intended medical use.”In the company’s words, NCT06308159 on ClinicalTrials.gov
- Tested for
- Beta-Thalassemia
- Main trialPhase 1/2
- “This is an interventional study to evaluate the safety and efficacy of autologous Hematopoietic Stem and Progenitor Cells (HSPCs) transduced with lentiviral vector encoding functional hemoglobin subunit beta (HBB) gene in patients with transfusion-dependent beta-thalassemia.”In the company’s words, NCT06308159 on ClinicalTrials.gov
Other drugs for Beta-Thalassemia
- CTX001Vertex Pharmaceuticals · Phase 3
- REGN7999Regeneron · Phase 2
- BRL-101Bioray Laboratories · Phase 1/2
- 9MW3011Mabwell · Phase 1
- LuspaterceptCelgene · Marketed (Phase 4 trial)
Coming up1
- 1 Aug 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 1 Aug 2027 | An Open-label Study of a Gene Therapy Product (Vebeglogene Autotemcel) in Transfusion Dependent Beta-Thalassemia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026